Clinical Trials Logo

Clinical Trial Summary

The purpose of this observational study is to understand real-world oral anticoagulants (OAC) (warfarin, apixaban, dabigatran, edoxaban and rivaroxaban) usage for non-valvular atrial fibrillation (NVAF) patients.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT05027061
Study type Observational
Source Bristol-Myers Squibb
Contact Recruiting sites have contact information. Please contact the si
Phone please email:
Email [email protected]
Status Recruiting
Start date April 2, 2021
Completion date September 30, 2021

See also
  Status Clinical Trial Phase
Recruiting NCT03887780 - A Study to Evaluate the Safety and Effectiveness of Rivaroxaban (Xarelto) for Prevention of Stroke and Systemic Embolism in Indian Patients With Non-valvular Atrial Fibrillation (NVAF)
Completed NCT02954237 - AMPLATZERâ„¢ Cardiac Plug Observational Post-Approval Study (ACP PAS China)
Completed NCT01598051 - Xarelto [SPAF-QOL] Post-marketing Surveillance in Japan
Recruiting NCT04356989 - Study to Gain Information on the Drug Xarelto for the Prevention of Brain Attack and Blockage of an Artery in the Non-central Nervous System Due to Irregular Heartbeat in Taiwanese Patients Suffering From Decreased Renal Function
Recruiting NCT03234114 - Optimal Antithrombotic Therapy for ACS Patients Concomitant With AF and Implanted With New-generation DES (OPTIMA-3, 4) Phase 4
Active, not recruiting NCT03746301 - Xarelto on Prevention of Stroke and Non-Central Nervous Systemic Embolism in Renally Impaired Korean Patients With Non-valvular Atrial Fibrillation
Not yet recruiting NCT05022758 - A Study to Learn Whether There Are Differences in the Kidney's Ability to Work Properly in Korean Patients With Non-valvular Atrial Fibrillation (Irregular and Often Rapid Heartbeat Not Caused by a Heart Valve Problem) Treated With Rivaroxaban as Compared to Those Treated With Warfarin
Active, not recruiting NCT02663076 - Factor XA - Inhibition in RENal Patients With Non-valvular Atrial Fibrillation - Observational Registry
Withdrawn NCT02153424 - Early Post-marketing Study of Eliquis (Apixaban) N/A